A global, multi-centre phase I/II clinical trial of gene therapy candidate SHP-654 for Haemophilia A.

Trial Profile

A global, multi-centre phase I/II clinical trial of gene therapy candidate SHP-654 for Haemophilia A.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs SHP 654 (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Oct 2017 According to a Shire media release, company received FDA clearance for the IND application it submitted earlier this year and anticipates to start the trial by the end of 2017.
    • 10 Jul 2017 New trial record
    • 06 Jul 2017 According to a Shire media release, company has submitted investigational new drug application (IND) to FDA for gene therapy candidate SHP-654 for treatment of Hemophilia A.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top